ICD-10-CM 2027 diagnosis code
Z17.4Combined receptor status
Z17.4 is a header code, so it can't be reported by itself. Choose one of the 2 more specific codes beneath it.
Code last changed in FY2025 (effective October 1, 2024). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data
About Z17.4
Z17.4 is the ICD-10-CM diagnosis code for combined receptor status. It belongs to category Z17 (estrogen, and other hormones and factors receptor status), block Z17 (estrogen, and other hormones and factors receptor status) and chapter 21 (factors influencing health status and contact with health services). It is a header code, so it can't be reported by itself; one of its 2 subcodes must be used instead.
Within Z17 (estrogen, and other hormones and factors receptor status), Z17.4 is specifically for combined receptor status. Related codes cover estrogen receptor positive status [ER+] (Z17.0), estrogen receptor negative status [ER-] (Z17.1), Progesterone receptor status (Z17.2) and human epidermal growth factor 2 receptor (Z17.3).
To report this condition, pick the subcode that matches the documentation: Z17.41 (positive) and Z17.42 (negative).
Code first malignant neoplasm, such as: malignant neoplasm of breast (C50.-) and malignant neoplasm of ovary (C56.-).
It was added in FY2025, effective October 1, 2024.
Specific codes under Z17.4
Coding notes
- Assign a code from subcategory Z17.4- when only a combined receptor status is documented
Notes that apply from higher levels
Instructions written at a parent level also apply to Z17.4.
Broader instructions also apply from Chapter 21: Factors influencing health status and contact with health services.
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2025 (effective 10/1/2024): Added
- No changes since FY2025.
Common questions about Z17.4
Is Z17.4 billable?
- No. Z17.4 is a header code. Report one of its more specific subcodes instead.